AI Article Synopsis
- The study is investigating the effectiveness of different doses of dexamethasone (20 mg vs 6 mg) in treating COVID-19 patients with moderate to severe ARDS requiring oxygen or mechanical ventilation.
- Three hundred adults will be randomized into two treatment groups and followed for up to 360 days, with the primary focus on ventilator-free days and secondary outcomes including mortality and quality of life.
- Conducted across ten university hospitals in the Czech Republic, the trial seeks to determine the optimal dosing for improved health outcomes in critical COVID-19 patients.
Article Abstract
Background: Since December 2019, SARS-CoV-2 virus has infected millions of people worldwide. In patients with COVID-19 pneumonia in need of oxygen therapy or mechanical ventilation, dexamethasone 6 mg per day is currently recommended. However, the dose of 6 mg of dexamethasone is currently being reappraised and may miss important therapeutic potential or may prevent potential deleterious effects of higher doses of corticosteroids.
Methods: REMED is a prospective, open-label, randomised controlled trial testing the superiority of dexamethasone 20 mg (dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10) vs 6 mg administered once daily intravenously for 10 days in adult patients with moderate or severe ARDS due to confirmed COVID-19. Three hundred participants will be enrolled and followed up for 360 days after randomization. Patients will be randomised in a 1:1 ratio into one of the two treatment arms. The following stratification factors will be applied: age, Charlson Comorbidity Index, CRP levels and trial centre. The primary endpoint is the number of ventilator-free days (VFDs) at 28 days after randomisation. The secondary endpoints are mortality from any cause at 60 days after randomisation; dynamics of the inflammatory marker, change in WHO Clinical Progression Scale at day 14; and adverse events related to corticosteroids and independence at 90 days after randomisation assessed by the Barthel Index. The long-term outcomes of this study are to assess long-term consequences on mortality and quality of life at 180 and 360 days. The study will be conducted in the intensive care units (ICUs) of ten university hospitals in the Czech Republic.
Discussion: We aim to compare two different doses of dexamethasone in patients with moderate to severe ARDS undergoing mechanical ventilation regarding efficacy and safety.
Trial Registration: EudraCT No. 2020-005887-70. ClinicalTrials.gov NCT04663555. Registered on December 11, 2020.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760569 | PMC |
| http://dx.doi.org/10.1186/s13063-021-05963-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
BAY 2413555 is a novel selective and reversible positive allosteric modulator of the type 2 muscarinic acetylcholine (M2) receptor, aimed at enhancing parasympathetic signaling and restoring cardiac autonomic balance for the treatment of heart failure (HF). This study tested the safety, tolerability and pharmacokinetics of this novel therapeutic option. REMOTE-HF was a multicenter, double-blind, randomized, placebo-controlled, phase Ib dose-titration study with two active arms.
View Article and Find Full Text PDFTrivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.
Nat Commun
December 2024
Laboratory of Aging Research and Cancer Drug Target, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
The immune escape capacities of XBB variants necessitate the authorization of vaccines with these antigens. In this study, we produce three recombinant trimeric proteins from the RBD sequences of Delta, BA.5, and XBB.
View Article and Find Full Text PDFAssociations of NETs with inflammatory risk and clinical predictive value in large artery atherosclerosis stroke: a prospective cohort study.
Front Immunol
December 2024
Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background And Objective: Neutrophil extracellular traps (NETs) with inflammatory risk are important contributors to cardiovascular disease, but no definitive information is available in large artery atherosclerotic (LAA) stroke. This study aims to investigate the association between NETs with related inflammatory biomarkers and prognosis of LAA stroke in the Chinese population.
Methods: A prospective study involving 145 LAA stroke cases and 121 healthy controls was conducted.
Evaluation of protective immunity in chickens vaccinated with combined IB H120/D274 and IB H120 against IS/1494/06 in Iran.
Arch Razi Inst
June 2024
Department of Clinical Science, Faculty of Veterinary Medicine, Karaj Branch, Islamic Azad University, Alborz, Iran.
Infectious bronchitis virus (IBV) has a variety of serotypes that cause many problems in the poultry industry. Two H120 and H120-D274 live vaccines were evaluated against strain IS/1494/06 (variant 2) IBV challenge. The study aimed to determine whether it was possible to achieve success in controlling disease symptoms and pathological lesions and reducing virus shedding by combining two types of vaccines against different severities of poultry IBV.
View Article and Find Full Text PDFEfficacy and Safety of Tranexamic Acid on Hidden Blood Loss in Osteoporotic Vertebral Compression Fractures Patients Treated with Percutaneous Kyphoplasty: A Prospective Randomized Controlled Trial.
Ther Clin Risk Manag
December 2024
Department of Orthopedics, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China.
Purpose: To evaluate the efficacy and safety of intravenous tranexamic acid (TXA) in patients undergoing percutaneous kyphoplasty (PKP), and identify the factors influencing hidden blood loss (HBL).
Methods: This randomized, placebo-controlled trial included 146 patients undergoing PKP surgery from September 2023 to July 2024. Patients were randomly assigned into the TXA group (75 patients received 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!